Actualizaciones regulatorias

MHRA reminds that there is no evidence linking paracetamol use in pregnancy to autism, reaffirming it as the first‑choice pain reliever for pregnant women.

The NGPod handheld device and sensor for nasogastric tube placement are being withdrawn in the UK after the manufacturer ceased trading; users must quarantine remaining units.

The UK Medicines and Healthcare products Regulatory Agency released a list of Field Safety Notices covering 17‑21 August 2026.

The MHRA’s annual MedSafetyWeek runs 3‑9 Nov 2025, focusing on the theme ‘we can all help make medicines safer’.

The Commission on Human Medicines has approved new prescribing guidance for isotretinoin and is gathering data from dermatology services for future updates.

The MHRA notes rare cases of idiopathic intracranial hypertension in mesalazine users and will update product information with a warning.

MHRA alerts that the transition to a new Rybelsus® tablet formulation, with different labeled doses but bioequivalent, may cause medication errors and patient harm.

The UK Medicines and Healthcare products Regulatory Agency has re‑examined safety warnings on gabapentin, pregabalin, benzodiazepines and Z‑drugs, with findings published in a Public Assessment Report.

The CHM has endorsed updated risk‑minimisation measures for isotretinoin after reviewing the 2023 measures, urging healthcare professionals to review them.

The MHRA has revised product information for all GLP‑1 and dual GLP‑1/GIP receptor agonists to emphasize the risk of acute pancreatitis, including necrotising and fatal cases.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) notes that non‑arteritic anterior ischemic optic neuropathy (NAION) has been reported very rarely in patients using semaglutide (Wegovy, Ozempic, Rybelsus).

MHRA’s safety review leads to IXCHIQ vaccine no longer being indicated for adults over 60 years.